Company intelligence / Profile preview

Callahero

Seattle, Washington, United States6sense.com ↗

Ownership: Private
Development stage: Other

Overview

Callio Therapeutics has launched with a $187 million Series A to advance its multi-payload antibody-drug conjugate (ADC) platform. Its lead program, a HER2-targeted dual-payload ADC for breast cancer, has shown promising preclinical results and will enter clinical proof-of-concept studies. The company aims to overcome limitations of single-payload ADCs by delivering rational drug combinations directly to tumor cells.

Therapeutic areas: OncologyPsychiatry
Modalities: Antibody-drug conjugateBiologic
Industry: Biotech

Partnerships

Hummingbird Bioscience (exclusive licensee of technology and programs)

Beyond the preview

Go deeper on Callahero.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Callahero.

Explore the full profile